European Journal of Nuclear Medicine

, Volume 24, Issue 6, pp 609–614 | Cite as

Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon mission tomography

  • Zuzana Walker
  • Durval C. Costa
  • Anthony G. Janssen
  • Rodney W. H. Walker
  • Gillian Livingstone
  • Cornelius L. E. Katona
Original Article


Dementia with Lewy bodies (DLB) can at present only be diagnosed with certainty by neuropathological examination. Diagnosis during life remains at best probable, based on the presence of symptoms known from autopsy studies to be frequently associated with DLB. The greatest practical clinical problem lies in distinguishing DLB arid Alzheimer's disease (AD). In DLB there is a considerable degeneration of nigral neurones with depletion of striatal dopamine. In contrast, AD is not associated with significant changes in dopamine metabolism. Iodine-123 iodobenzamide single-photon emission tomography (IBZM-SPET) measures post-synaptic dopamine D2 neuroreceptor availability in the corpus striatum, but is nevertheless a method for assessing the integrity of the nigrostriatal dopaminergic pathway. Sixteen clinically diagnosed DLB patients, 15 normal controls arid 13 AD patients underwent IBZM-SPET. All subjects were scanned 1.5–2 h after intravenous injection of 185 MBq of123I-IBZM. Circular regions of iriterest were employed to calculate radioactivity ratios in each hemisphere as follows: caudate nucleus/frontal cortex, putamen/frontal cortex arid caudate nucleus/putamen. The DLB patients had significantly lower left caudate/putamen ratios (95% confidence intervals: DLB 0.893–0.965, AD 0.972–1.175, controls 1.031–1.168) than either controls or AD patients, and significantly lower right caudate/putamen ratios (95% confidence intervals: DLB 0.926–1.019, AD 0.954–1.103, controls 1.027–1.144) chan controls. Our data suggest that patients with DLB diagnosed by clinical criteria have changes in striatal post-synaptic D2 receptors. This may be of value in distinguishing DLB from AD during life.

Key words

Dementia with Lewy bodies Alzheimer's disease D2 receptors Iodine-123 iodobenzamide Single-photon emission tomography 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Byrne EJ, Lowe J, Lennox G, Godwin-Austen RB. Diffuse Lewy body disease; clinical features in 15 cases.J Neurol Neurosurg Psychiatry 1989; 52: 709–717.Google Scholar
  2. 2.
    Lennox G, Lowe J, Landon M, Byrne EJ, Mayer RJ, Godwin-Austen RB. Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry.J Neurol Neurosurg Psychiatry 1989; 52: 1236–1247.Google Scholar
  3. 3.
    Dickson DW, Crystal HA, Mattiace HA, et al. Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques.Acta Neuropathol (Berl) 1989; 78: 572–584.Google Scholar
  4. 4.
    McKeith IG. Senile dementia of Lewy body type — a review of clinical and pathological features: implications for treatment.Int J Geriatr Psychiatry 1995; 10: 919–926.Google Scholar
  5. 5.
    Hely MA, Reid WGJ, Halliday GM, et al. Diffuse Lewy body disease: clinical features in nine cases without coexistent Alzheimer's disease.J Neurol Neurosurg Psychiatry 1996; 60: 531–538.Google Scholar
  6. 6.
    Shergill S, Mullan L, D'Ath PJ, Katona CLE. What is the clinical prevalence of Lewy body dementia.Int J Geriatr Psychiatr 1994; 9: 907–912.Google Scholar
  7. 7.
    Byrne EJ, Lennox G, Godwin-Austen RB, et al. Diagnostic criteria for dementia associated with cortical Lewy bodies.Dementia 1991; 2: 283–284.Google Scholar
  8. 8.
    McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK. Operational criteria for senile dementia of Lewy body type (SDLT).Pathol Med 1992; 22: 911–922.Google Scholar
  9. 9.
    Byrne EJ. Cortical Lewy body disease: an alternative view. In: Levy R, et al.Developments in dementia and functional disorders in the elderly. Petersfield, UK: Wrightson Biomedical, 1995:21–30.Google Scholar
  10. 10.
    McKeith IG, Fairbairn AF, Bothwell RA, et al. An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type.Neurology 1994; 44: 872–877.Google Scholar
  11. 11.
    Förstl H, Sattel H, Bahro M. A1zheimer's disease: clinical features.Int Rev Psychiatry 1993; 5: 327–349.Google Scholar
  12. 12.
    McKeith IG, Galasko D, Wilcock GK, Byrne EJ. Lewy body dementia — diagnosis and treatment.Br J Psychiatry 1995; 167: 709–717.Google Scholar
  13. 13.
    McKeith IG. Cortical Lewy body disease: the view from Newcastle. In: Levy R, et al.Developments in dementia and functional disorders in the elderly. Petersfield, UK: Wrightson Biomedical; 1995: 9–20.Google Scholar
  14. 14.
    Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity.Brain 1991; 114: 2283–2301.Google Scholar
  15. 15.
    Koller WC. When does Parkinson's disease begin?Neurology 1992; 42: 27–31.Google Scholar
  16. 16.
    Perry EK, Marshall E, Perry RH, et al. Cholinergie and dopaminergic activities in senile dementia of Lewy body type.Alzheimer Dis Assoc Disord 1990; 4: 87–95.Google Scholar
  17. 17.
    Burn DJ, Mark MH, Playford ED, et al. Parkinson's disease in twins studied with18F-dopa and positron emission tomography.Neurology 1992; 42: 1894–1900.Google Scholar
  18. 18.
    Sawle GV, Wroe SJ, Lees AJ, Brooks DJ, Frackowiak RSJ. The identification of presymptomatic Parkinsonism: clinical and [18F]-dopa positron emission tomography studies in an Irish kindred.Ann Neurol 1992; 32: 609–617.Google Scholar
  19. 19.
    Tyrell PJ, Sawle GV, Ibanez V, et al. Clinical and positron emission tomographie studies in the “extrapyramidal syndrome” of dementia of Alzheimer's type.Arch Neurol 1990; 47: 1318–1328.Google Scholar
  20. 20.
    Brooks DJ. Functional imaging in relation to parkinsonian syndromes.J Neurol Neurosurg Psychiatry 1993; 115: 1–17.Google Scholar
  21. 21.
    Costa DC, Verhoeff NPLG, Cullum ID, et al. In vivo characterisation of 3-iodo-6-methoxybenzamide123I in humans.Eur J Nucl Med 1990; 16: 813–816.Google Scholar
  22. 22.
    McKhann G, Drachman D, Folstein MF, Katzman R, Price D, Standlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease.Neurology 1984: 34; 939–944.Google Scholar
  23. 23.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases.J Neurol Neurosurg Psychiatry 1992; 55: 181–184.Google Scholar
  24. 24.
    Folstein MF, Folstein SE, HcHugh PR. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician.J Psychiatr Res 1975; 12: 189–198.Google Scholar
  25. 25.
    Pattie AH. A survey version of the clifton assessment procedures for the elderly (CAPE).Br Clin Psychol 1981; 20: 173–178.Google Scholar
  26. 26.
    Yesavage JA. Geriatric Depression Scale.Psychopharmacol Bull 1988; 24: 709–711.Google Scholar
  27. 27.
    Berl L. Clinical Dementia Rating (CDR).Psychopharmacol Bull 1988; 24: 637–639.Google Scholar
  28. 28.
    Roth M, Tym E, Mountjoy CQ, et al. CAMDEX: a standardised instrument for the diagnosis of mental disorders in the elderly with special reference to the early detection of dementia.Br J Psychiatry 1986; 149: 698–709.Google Scholar
  29. 29.
    Brücke T, Podreka I, Angelberger P, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.J Cereb Blood Flow Metab 1991; 11: 220–228.Google Scholar
  30. 30.
    Brooks DJ, Ibanez J, Sawle GV, et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with11C-raclopride and positron emission tomography.Ann Neurol 1992; 31: 184–192.Google Scholar
  31. 31.
    Laulumaa V, Kuikka JT, Soininen H, Bergström K, Länsimies E, Riekkinen P. Imaging of D2 dopamine receptors of patients with Parkinson's disease using single photon emission tomography and iodobenzamide I 123.Arch Neurol 1993; 50: 509–512.Google Scholar
  32. 32.
    Pizzolato G, Chierichetti F, Rossato A, et al. Dopamine receptor SPET imaging in Parkinson's disease: a [123I]-IBZM and [99mTc]-HM-PAO study.Eur Neurol 1993; 33: 143–148.Google Scholar
  33. 33.
    Rinne UK, Laihinen A, Rinne JO, Någren K, Bergman J, Ruotsalainen U. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease.Mov Disord 1990; 5: 55–59.Google Scholar
  34. 34.
    Rinne JO, Laihinen A, Rinne UK, Någren K, Bergman J, Ruotsalainen U. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease.Mov Disord 1993; 8: 134–138.Google Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • Zuzana Walker
    • 1
  • Durval C. Costa
    • 2
  • Anthony G. Janssen
    • 3
  • Rodney W. H. Walker
    • 4
  • Gillian Livingstone
    • 5
  • Cornelius L. E. Katona
    • 1
  1. 1.University College London Medical School, London and Princess Alexandra HospitalHarlowUK
  2. 2.University College London Medical School, London and University College London Hospitals, NHS TrustLondonUK
  3. 3.Eindhoven University of Technology and Amersham Cygne b.v.The Netherlands
  4. 4.St. Bartholomew's Hospital, London and Princess Alexandra HospitalHarlowUK
  5. 5.University College London Medical School, London, and Whittington HospitalLondonUK

Personalised recommendations